The EDEM2 Knockout AGS Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the EDEM2 gene within the AGS human gastric adenocarcinoma cell line. This model offers a robust platform for examining EDEM2 function in glycoprotein quality control and ER-associated degradation (ERAD) in a malignant epithelial environment. The heterogeneous polyclonal cell population supports population-level functional studies without requiring clonal isolation, facilitating diverse downstream assays.
Derived from a human gastric adenocarcinoma, the AGS cell line serves as an established in vitro model for gastric cancer research. These malignant epithelial cells enable investigation of tumor cell biology, drug responsiveness, and oncogenic signaling pathways. Hosting the EDEM2 knockout in AGS cells permits analysis of ERAD pathway dynamics and ER stress responses in a cellular context inherently relevant to gastric carcinogenesis and tumor progression.
EDEM2 encodes a mannosidase-like lectin that recognizes mannose-trimmed N-glycans on misfolded glycoproteins in the ER, targeting them for proteasomal degradation via the ERAD pathway. It associates with the lectins calnexin and calreticulin, the mannose-binding factors OS9 and XTP3-B, and the retrotranslocation machinery comprising SEL1L, HRD1, and Derlin. Transcription of EDEM2 is induced by ER stress through the UPR sensors ATF6, IRE1, and PERK, which are triggered by agents like tunicamycin and thapsigargin. Functionally, EDEM2-mediated substrate clearance attenuates UPR signaling, and its activity is synchronized with the mannosidases MAN1A and MAN1B, which process the N-glycans recognized by EDEM2.
In AGS cells, EDEM2 disruption is anticipated to impair ERAD efficiency, resulting in accumulation of misfolded glycoproteins and heightened ER stress. This may shift UPR signaling toward either pro-survival or pro-apoptotic outcomes, a balance frequently dysregulated in gastric cancer where adaptation to chronic ER stress supports tumor growth and chemoresistance. Exploiting this model can therefore elucidate how compromised glycoprotein quality control influences malignant traits such as proliferation, metastasis, and sensitivity to ER stress-inducing chemotherapeutics. Additionally, it offers mechanistic insights relevant to congenital disorders of glycosylation and other ER stress-related pathologies.
Researchers can apply these polyclonal knockout cells to a range of experimental analyses, including western blotting for EDEM2 and ER stress markers (e.g., BiP, CHOP), RT-qPCR profiling of UPR target genes, and cycloheximide chase assays to assess glycoprotein degradation. Complementary approaches encompass flow cytometry with ER stress reporters, immunofluorescence examination of ER architecture, and cell viability testing under ER stress conditions to screen pharmacological modulators. Collectively, the EDEM2 Knockout AGS Polyclonal Cells provide a versatile resource for dissecting ERAD biology in gastric cancer and evaluating therapeutic strategies that target the UPR. For further technical inquiries, please contact Ascent Research.
